Latest Cancer Research Institute Stories
New Campaign Raises Awareness of the Importance of the Immune System in Cancer Prevention and Treatment LOS ANGELES and NEW YORK, June 13, 2013 /PRNewswire-USNewswire/ -- Stand Up To Cancer (SU2C) and the Cancer Research Institute (CRI) have teamed up to develop a new print public service announcement featuring NCIS star Mark Harmon. The PSA, entitled "I Am My Own Secret Weapon," is designed to increase awareness about cancer immunotherapy, which mobilizes our immune systems to...
Contributed by Cancer Research Institute NEW YORK, June 2, 2013 /PRNewswire/ -- At six years old Emily Whitehead was only two weeks from a bone marrow transplant when her leukemia came back for a second time. (Photo: http://photos.prnewswire.com/prnh/20130602/LA24333) Emily, who goes by Emma, had been fighting acute lymphoblastic leukemia since she was five years old. With her second relapse, she and her parents were out of options -- until she was offered a place as the first...
Series of five webinars will discuss cutting-edge research and breakthroughs in immune treatments for cancers and ways to get involved in immunotherapy NEW YORK, May 22, 2013 /PRNewswire/ -- The Cancer Research Institute (CRI), a New York-based nonprofit organization committed to developing immune system-based cancer treatments, is holding a series of five webinars in June to talk about breakthroughs in cancer immunotherapy research and treatments as part of Cancer Immunotherapy...
The Cancer Research Institute (CRI) declares June “Cancer Immunotherapy Awareness Month” to increase awareness of cancer immunotherapy, a new class of cancer treatment that mobilizes the immune system to fight the disease and represents the most immediate hope for curing patients with any type of cancer. The month will feature educational webinars offered free to the public from top experts in cancer immunotherapy, and a Wear White for a Cure Day on June 7. New York, NY (PRWEB) May 08,...
NEW YORK and GAITHERSBURG, Md., Oct. 9, 2012 /PRNewswire/ -- The Cancer Research Institute (CRI), the Ludwig Institute for Cancer Research and MedImmune, the global biologics arm of AstraZeneca, today announced that they have signed a collaboration agreement to advance the research of immunotherapy in cancer. Specifically, the research will focus on clinical trials to test novel combinations of immunotherapies, including three investigational monoclonal antibodies from MedImmune's...
MAINZ, Germany and NEW YORK, July 26, 2012 /PRNewswire/ -- Increasing transparency and quality of immune response measurements The Association for Cancer Immunotherapy (CIMT) Immunoguiding Program (CIP) and the Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute (CRI) today announced the publication of a letter in Immunity discussing the results of an unique vetting process that involved multiple international groups and individuals and has...
TORONTO, Feb. 3, 2011 /PRNewswire/ -- Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced the company has entered into a Manufacturing Services Agreement with Oncovir, Inc., a specialty pharma company based in Washington DC, dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders. Dalton Pharma Services will provide API manufacturing...
CAMBRIDGE, Mass. and NEW YORK, Dec. 1, 2010 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) -- a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research -- today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody...
Scott & White's Cancer Research Institute (CRI) has launched two clinical trials targeting cancers that affect both adults and children."These studies may lead to eventual development of agents that we hope will improve quality and duration of life," said Arthur Frankel, M.D., director of the CRI, and director of Scott & White's Cancer Center and division of hematology/oncology.One of the studies aims to find the maximum safest dose of an agent for treatment of T-cell...
